Subscription, allocation and payment

The Rights Issue was subscribed to approximately SEK 6.3 million including pre-subscription commitments of approximately SEK 0.26 million, which corresponds to a subscription rate of approximately 27.3 percent. Cyxone is thus provided approximately SEK 6.3 million before transaction related costs.

A total of 150,815,096 shares were subscribed for with the support of pre-emptive subscription rights, including pre-subscription commitments. In total, 6,631,167 shares were subscribed without the support of pre-emptive subscription rights. Through the Rights Issue, 157,446,263 new shares will thus be issued. The subscribers who are allocated shares without preferential rights will receive settlement notes, which are planned to be sent out today, after a formal board decision on allocation. Allotted shares without pre-emptive right shall be paid in accordance with the instructions on the settlement note.

Number of shares and share capital

When the Rights Issue has been registered with the Swedish Companies Registration Office, the total number of shares will have increased by 157,446,263 shares, from 215,926,036 shares to 373,372,299 shares, and the Company's share capital will upon registration, have increased by SEK 6,297,850.52, from SEK 8,637,041.44 to SEK 14,934,891.96. The shareholders who have not participated in the Rights Issue will be subject to a dilution effect corresponding to approximately 42.2 percent of the votes and capital.

Trading in BTA

Trading in BTA's will take place on Nasdaq First North Growth Market until after the Rights Issue has been registered with the Swedish Companies Registration Office. The registration is expected to take place around 30 August 2024.

Advisors

In connection with the Rights Issue, Sedermera Corporate Finance AB assists the Company with project management, Markets & Corporate Law Nordic AB with legal advice and Hagberg & Aneborn Fondkommission AB with issuing services.

For more information about the Rights Issue, please contact:

Sedermera Corporate Finance AB
Phone: +46 (0)40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se

For more information about the Company, please contact:

Kjell Stenberg, CEO
Phone: +46 (0)70 781 88 08
E-mail: kjell.g.stenberg@cyxone.com
www.cyxone.com

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com